CureVac (NASDAQ:CVAC) (NASDAQ: CVAC) is a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, specializing in the development of messenger RNA (mRNA)-based therapeutics and vaccines. The company’s proprietary mRNA technology platform is designed to harness the body’s natural cellular machinery to produce proteins that address a wide range of diseases. Since its founding in 2000, CureVac has focused on optimizing mRNA stability, delivery and manufacturing processes to create modular drug candidates that can be rapidly designed and scaled.
The company’s product pipeline spans both prophylactic and therapeutic applications. In infectious diseases, CureVac is advancing vaccine candidates targeting pathogens such as rabies and influenza, leveraging its mRNA platform for rapid response and dose sparing. In oncology, it is developing individualized cancer immunotherapies that direct the immune system to recognize and eliminate tumor cells. Additional programs are exploring mRNA-based treatments for rare diseases and soluble protein replacement therapies.
CureVac operates collaboration and partnership agreements with global pharmaceutical and biotechnology firms to strengthen its R&D capabilities and expand manufacturing capacity. The company has established strategic alliances to support late-stage development and commercialization, including agreements for large-scale mRNA production in Europe and North America. This network of partnerships allows CureVac to accelerate clinical development timelines and prepare for potential global rollouts of its vaccine and therapeutic candidates.
Led by Chief Executive Officer Franz‐Werner Haas, CureVac’s management team combines expertise in molecular biology, clinical development and regulatory affairs. Over the past decade, the company has built a multidisciplinary workforce of scientists and engineers working at its research sites in Tübingen, Boston and other innovation hubs. As CureVac continues to advance its mRNA technology, it aims to deliver a new class of safe, effective and scalable treatments that address unmet medical needs worldwide.
